236 related articles for article (PubMed ID: 19028525)
1. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir.
Seifer M; Patty A; Serra I; Li B; Standring DN
Antiviral Res; 2009 Feb; 81(2):147-55. PubMed ID: 19028525
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
Qi X; Xiong S; Yang H; Miller M; Delaney WE
Antivir Ther; 2007; 12(3):355-62. PubMed ID: 17591025
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
Zaaijer HL; Takkenberg RB; Weegink CJ; Rebers SP; Menting S; Reesink HW; Schinkel J; Molenkamp R
J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
6. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
[TBL] [Abstract][Full Text] [Related]
7. [Resistance mutation patterns of hepatitis B virus in patients with suboptimal response to adefovir dipivoxil therapy after lamivudine resistance].
Wu ZP; Hang T; Gao YT; Li Y; Liu T; Jing L; Liu L; Du Z
Zhonghua Gan Zang Bing Za Zhi; 2010 Jul; 18(7):498-501. PubMed ID: 20678438
[TBL] [Abstract][Full Text] [Related]
8. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
[TBL] [Abstract][Full Text] [Related]
9. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro.
Delaney WE; Yang H; Miller MD; Gibbs CS; Xiong S
Antimicrob Agents Chemother; 2004 Oct; 48(10):3702-10. PubMed ID: 15388423
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains.
Herbers U; Amini-Bavil-Olyaee S; Mueller A; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2013 Feb; 20(2):141-8. PubMed ID: 23301549
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.
Svarovskaia ES; Curtis M; Zhu Y; Borroto-Esoda K; Miller MD; Berg T; Lavocat F; Zoulim F; Kitrinos KM
J Viral Hepat; 2013 Feb; 20(2):131-40. PubMed ID: 23301548
[TBL] [Abstract][Full Text] [Related]
12. rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B.
Liu LJ; Wang JH; Du SC; Tian JH; Yang RF; Wei L
J Viral Hepat; 2010 Mar; 17 Suppl 1():66-72. PubMed ID: 20586936
[TBL] [Abstract][Full Text] [Related]
13. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Sheldon J; Luedde T; Trautwein C; Tacke F
Hepatology; 2009 Apr; 49(4):1158-65. PubMed ID: 19263474
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors.
Niu C; Bao H; Tolstykh T; Micolochick Steuer HM; Murakami E; Korba B; Furman PA
Antivir Ther; 2010; 15(3):401-12. PubMed ID: 20516559
[TBL] [Abstract][Full Text] [Related]
15. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.
Billioud G; Pichoud C; Puerstinger G; Neyts J; Zoulim F
Antiviral Res; 2011 Nov; 92(2):271-6. PubMed ID: 21871497
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous detection of hepatitis B virus genotypes and mutations associated with resistance to lamivudine, adefovir, and telbivudine by the polymerase chain reaction-ligase detection reaction.
Wang YZ; Xiao JH; Liu LG; Ye CY; Shen HY; Xu TM; Zhu KZ
Braz J Infect Dis; 2011; 15(6):560-6. PubMed ID: 22218515
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of Adefovir, Tenofovir and Entecavir Resistance: Molecular Modeling Studies of How A Novel Anti-HBV Agent (FMCA) Can Overcome the Drug Resistance.
Rawal RK; Konreddy AK; Chu CK
Curr Med Chem; 2015; 22(34):3922-32. PubMed ID: 26336997
[TBL] [Abstract][Full Text] [Related]
18. Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance.
Menéndez-Arias L; Álvarez M; Pacheco B
Curr Opin Virol; 2014 Oct; 8():1-9. PubMed ID: 24814823
[TBL] [Abstract][Full Text] [Related]
19. Telbivudine in the treatment of chronic hepatitis B.
Nash K
Adv Ther; 2009 Feb; 26(2):155-69. PubMed ID: 19225726
[TBL] [Abstract][Full Text] [Related]
20. Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy.
van Bömmel F; Trojan J; Deterding K; Wedemeyer H; Wasmuth HE; Hüppe D; Möller B; Bock FJ; Feucht HH; Berg T
Antivir Ther; 2012; 17(6):1049-58. PubMed ID: 22892524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
